Stock TFFP TFF PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company TFF Pharmaceuticals, Inc.

Equities

TFFP

US87241J2033

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.922 USD -4.21% Intraday chart for TFF Pharmaceuticals, Inc. +13.24% -58.38%
Apr. 15 TFF Pharmaceuticals, Inc. Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial Following Oral Presentation At the Ishlt 44Th Annual Late-Breaking Clinical Science Abstract Sessions CI
Apr. 08 TFF Pharmaceuticals Files Equities Shelf MT

Business Summary

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicine into potent dry powder. It is focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. Its TFF technology platform has an applicability to convert any drug, including vaccines, small and large molecules, and biologics, into a dry powder for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF TAC (Tacrolimus Inhalation Powder) and TFF VORI (Voriconazole Inhalation Powder). TFF TAC is an inhaled dry powder formulation of tacrolimus, for the prophylaxis of organ rejection in patients receiving lung transplants, in combination with other immunosuppressants. TFF VORI is an inhaled dry powder formulation of voriconazole, for the treatment and prophylaxis of invasive pulmonary aspergillosis.

Number of employees: 19

Sales per Business

USD in Million2022Weight2023Weight Delta
Inhaled Dry Powder Drugs
100.0 %
0 100.0 % 1 100.0 % +48.02%

Sales per region

USD in Million2022Weight2023Weight Delta
United States and Australia
100.0 %
0 100.0 % 1 100.0 % +48.02%

Managers

Managers TitleAgeSince
Harlan Weisman CEO
 Chief Executive Officer 71 18-11-30
Kirk Coleman DFI
 Director of Finance/CFO 51 18-01-23
Zamaneh Mikhak CTO
 Chief Tech/Sci/R&D Officer 59 23-01-08
Anthony J. Hickey CTO
 Chief Tech/Sci/R&D Officer - -
Robert Mills BRD
 Director/Board Member 71 18-01-23
Bill Begien IRC
 Investor Relations Contact - 22-09-30
John J. Koleng PRN
 Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Stephen Rocamboli BRD
 Director/Board Member 52 18-11-30
Brandi Roberts BRD
 Director/Board Member 50 22-03-24
Thomas King BRD
 Director/Board Member 69 Dec. 12
Robert Mills BRD
 Director/Board Member 71 18-01-23
Harlan Weisman CEO
 Chief Executive Officer 71 18-11-30
Catherine C. Lee BRD
 Director/Board Member 50 Nov. 29
Michael A. Patane BRD
 Director/Board Member - Nov. 29

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 2,519,220 2,371,182 ( 94.12 %) 0 94.12 %

Shareholders

NameEquities%Valuation
Carlson Capital LP
7.699 %
193,960 7.699 % 1 M $
DRW Securities LLC
1.588 %
40,000 1.588 % 241 600 $
Westside Investment Management LLC
1.557 %
39,225 1.557 % 236 919 $
Vanguard Global Advisers LLC
1.345 %
33,873 1.345 % 204 593 $
Harlan Weisman
1.293 %
32,585 1.293 % 196 813 $
AIGH Capital Management LLC
1.170 %
29,482 1.170 % 178 071 $
Geode Capital Management LLC
0.6240 %
15,720 0.6240 % 94 949 $
Renaissance Technologies LLC
0.4564 %
11,497 0.4564 % 69 442 $
BlackRock Institutional Trust Co. NA
0.3385 %
8,527 0.3385 % 51 503 $
Zamaneh Mikhak
0.2144 %
5,400 0.2144 % 32 616 $

Company contact information

TFF Pharmaceuticals, Inc.

1751 River Run Suite 400

76107, Fort Worth

+817 438 6168

http://www.tffpharma.com
address TFF Pharmaceuticals, Inc.(TFFP)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for TFF Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.05 USD
Average target price
36 USD
Spread / Average Target
+1,080.33%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TFF PHARMACEUTICALS, INC. Stock TFF Pharmaceuticals, Inc.
-58.38% 7.68M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.59B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 40.65B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 40.57B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.77B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 24.81B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.17B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.7B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11.1B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. TFFP Stock
  4. Company TFF Pharmaceuticals, Inc.